Chemed’s CHE Roto-Rooter business has been registering robust performance over the past few quarters. A good solvency position buoys optimism. The company currently carries a Zacks Rank #2 (Buy). Over ...
VITAS Net Revenue: $391.4 million, an increase of 17.3% year-over-year. VITAS Admissions: 16,775, a 6.3% increase from the prior year. Average Daily Census (ADC) for VITAS: 21,785 patients, a 15.5% ...
VITAS Net Revenue: $407.7 million in Q3 2025, a 4.2% increase from the prior year. Roto-Rooter Revenue Increase: 1.1% in Q3 2025 compared to Q3 2024. VITAS Adjusted EBITDA: $70.4 million, a 3.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback